Product Information
METFORMIN ER 500 MG GASTRC-TB is a generic product labeled by ScieGen Pharmaceuticals, Inc., priced at $0.2710 per EA under NDC 50228044501. Its NADAC has been published 266 times since Sep 1, 2021.
FDA first approved this application on Apr 16, 2021. Its Orange Book therapeutic-equivalence code is AB3 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
500 mg/1
Manufacturer
ScieGen Pharmaceuticals, Inc.NDC
50228044501
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METFORMIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA213334FDA Approved
4/16/2021
TE Code
AB3
On Market Since
4/16/2021
Pharmacological Classes
Price Statistics
The NADAC for METFORMIN ER 500 MG GASTRC-TB has been published 266 times since Sep 1, 2021, and over the history we have for it it has declined 86.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2710 per EA |
|---|---|
| All-time high | $2.7019 (May 10, 2023) |
| All-time low | $0.2619 (Aug 19, 2026) |
| 52-week high | $0.3965 |
| 52-week low | $0.2619 |
| Median price | $0.6048 |
| Average price | $1.0729 |
| Largest weekly change | +107.3% (Feb 23, 2022) |
| Weeks tracked | 266 |
| Tracking since | Sep 1, 2021 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 39% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ScieGen Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Metformin Hydrochloride Extended-Release Tablets market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METFORMIN ER 500 MG GASTRC-TB?
The current National Average Drug Acquisition Cost (NADAC) for METFORMIN ER 500 MG GASTRC-TB, manufactured by ScieGen Pharmaceuticals, Inc., is $0.2710 per EA (NDC 50228044501), effective Sep 30, 2026.
How has the price of METFORMIN ER 500 MG GASTRC-TB changed over time?
Over the history we have for it, the NADAC for METFORMIN ER 500 MG GASTRC-TB has declined 86.6%. It has been tracked across 266 weekly CMS publications since Sep 1, 2021.
What are the highest and lowest recorded NADAC prices for METFORMIN ER 500 MG GASTRC-TB?
Since Sep 1, 2021, the NADAC for METFORMIN ER 500 MG GASTRC-TB has ranged from a low of $0.2619 (Aug 19, 2026) to a high of $2.7019 (May 10, 2023), with a median of $0.6048 per EA.
Are there cheaper alternatives to METFORMIN ER 500 MG GASTRC-TB?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METFORMIN ER 500 MG OSMOTIC TB, is $0.1644 per EA — about 39% below METFORMIN ER 500 MG GASTRC-TB.
Who manufactures METFORMIN ER 500 MG GASTRC-TB?
METFORMIN ER 500 MG GASTRC-TB (NDC 50228044501) is labeled by ScieGen Pharmaceuticals, Inc., and CMS classifies it as a generic product.